Apellis Pharmaceuticals shares are trading lower. The company presented post hoc data that reinforced the long-term efficacy and safety of EMPAVELI in adults with paroxysmal nocturnal hemoglobinuria for up to three years.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals' shares have declined following the presentation of post hoc data that supported the long-term efficacy and safety of EMPAVELI for up to three years in adults with paroxysmal nocturnal hemoglobinuria.
December 11, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock price has decreased after the company presented long-term data for EMPAVELI, which may have been expected to have a more positive impact.
The decline in Apellis Pharmaceuticals' stock price suggests that the market may have anticipated more favorable data or that the positive results were already priced in. The long-term efficacy and safety data are crucial for the continued adoption and sales of EMPAVELI, and the market reaction indicates that investors might have had higher expectations.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100